Suramin inhibits macrophage activation by human group IIA phospholipase A2, but does not affect bactericidal activity of the enzyme

[1]  R. Ward,et al.  Insights on calcium-independent phospholipid membrane damage by Lys49-PLA2 using tryptophan scanning mutagenesis of bothropstoxin-I from Bothrops jararacussu. , 2008, Biochimie.

[2]  M. Teresa Pisabarro,et al.  Mechanism of inhibition of human secretory phospholipase A2 by flavonoids: rationale for lead design , 2007, J. Comput. Aided Mol. Des..

[3]  R. Ward,et al.  Mapping of the structural determinants of artificial and biological membrane damaging activities of a Lys49 phospholipase A2 by scanning alanine mutagenesis. , 2007, Biochimica et biophysica acta.

[4]  R. Stábeli,et al.  Snake venom phospholipase A2 inhibitors: medicinal chemistry and therapeutic potential. , 2007, Current topics in medicinal chemistry.

[5]  R. Arni,et al.  Interfacial surface charge and free accessibility to the PLA2-active site-like region are essential requirements for the activity of Lys49 PLA2 homologues. , 2007, Toxicon : official journal of the International Society on Toxinology.

[6]  H. Buhr,et al.  Suramin Inhibits Not Only Tumor Growth and Metastasis but Also Angiogenesis in Experimental Pancreatic Cancer , 2007, Journal of Gastrointestinal Surgery.

[7]  M. Gelb,et al.  Secreted phospholipase A2 inhibitors are also potent blockers of binding to the M-type receptor. , 2006, Biochemistry.

[8]  Edward A Dennis,et al.  The phospholipase A2 superfamily and its group numbering system. , 2006, Biochimica et biophysica acta.

[9]  M. Triggiani,et al.  Activation of human inflammatory cells by secreted phospholipases A2. , 2006, Biochimica et biophysica acta.

[10]  Chien-Huang Lin,et al.  Lipoteichoic acid-induced nitric oxide synthase expression in RAW 264.7 macrophages is mediated by cyclooxygenase-2, prostaglandin E2, protein kinase A, p38 MAPK, and nuclear factor-kappaB pathways. , 2006, Cellular signalling.

[11]  W. Shafer,et al.  Antimicrobial peptides and endotoxin inhibit cytokine and nitric oxide release but amplify respiratory burst response in human and murine macrophages , 2005, Cellular microbiology.

[12]  J. Au,et al.  Nontoxic Suramin Treatments Enhance Docetaxel Activity in Chemotherapy-Pretreated Non-Small Cell Lung Xenograft Tumors , 2005, Pharmaceutical Research.

[13]  R. Arni,et al.  Inhibition of myotoxic activity of Bothrops asper myotoxin II by the anti-trypanosomal drug suramin. , 2005, Journal of molecular biology.

[14]  Shi-bo Tang,et al.  [The inhibiting effects of suramin on bFGF induced proliferation of cultured human RPE cells]. , 2005, [Zhonghua yan ke za zhi] Chinese journal of ophthalmology.

[15]  J. Holland,et al.  Quality of life impact of three different doses of suramin in patients with metastatic hormone‐refractory prostate carcinoma , 2004, Cancer.

[16]  C. Suschek,et al.  The role of iNOS in chronic inflammatory processes in vivo: is it damage-promoting, protective, or active at all? , 2004, Current molecular medicine.

[17]  R. Ward,et al.  Topology of the substrate-binding site of a Lys49-phospholipase A2 influences Ca2+-independent membrane-damaging activity. , 2004, The Biochemical journal.

[18]  M. Gallacci,et al.  Antagonism of myotoxic and paralyzing activities of bothropstoxin-I by suramin. , 2003, Toxicon : official journal of the International Society on Toxinology.

[19]  M. Gelb,et al.  Interfacial Kinetic and Binding Properties of the Complete Set of Human and Mouse Groups I, II, V, X, and XII Secreted Phospholipases A2 * , 2002, The Journal of Biological Chemistry.

[20]  J. Balsinde,et al.  Phospholipase A2 regulation of arachidonic acid mobilization , 2002, FEBS letters.

[21]  C. Betzel,et al.  Design of specific peptide inhibitors of phospholipase A2: structure of a complex formed between Russell's viper phospholipase A2 and a designed peptide Leu-Ala-Ile-Tyr-Ser (LAIYS). , 2002, Acta crystallographica. Section D, Biological crystallography.

[22]  C. Betzel,et al.  First structural evidence of a specific inhibition of phospholipase A2 by alpha-tocopherol (vitamin E) and its implications in inflammation: crystal structure of the complex formed between phospholipase A2 and alpha-tocopherol at 1.8 A resolution. , 2002, Journal of molecular biology.

[23]  P. A. Melo,et al.  Effect of suramin on myotoxicity of some crotalid snake venoms. , 2002, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

[24]  M. Gelb,et al.  The Antibacterial Properties of Secreted Phospholipases A2 , 2002, The Journal of Biological Chemistry.

[25]  J. Lim,et al.  Group IIA secretory phospholipase A2 stimulates inducible nitric oxide synthase expression via ERK and NF‐κB in macrophages , 2001, European journal of immunology.

[26]  W. B. Church,et al.  A Novel Approach to the Design of Inhibitors of Human Secreted Phospholipase A2 Based on Native Peptide Inhibition* 210 , 2001, The Journal of Biological Chemistry.

[27]  R. Ward,et al.  Refolding and purification of Bothropstoxin-I, a Lys49-phospholipase A2 homologue, expressed as inclusion bodies in Escherichia coli. , 2001, Protein expression and purification.

[28]  D. Wilton,et al.  The antibacterial properties of secreted phospholipases A(2). , 2000, Biochimica et biophysica acta.

[29]  A. Rademaker,et al.  A Pilot Trial of Suramin in Metastatic Breast Cancer to Assess Antiangiogenic Activity in Individual Patients , 2000, Oncology.

[30]  D. J. Mason,et al.  Flow Cytometric Monitoring of Antibiotic-Induced Injury in Escherichia coli Using Cell-Impermeant Fluorescent Probes , 2000, Antimicrobial Agents and Chemotherapy.

[31]  R. Schevitz,et al.  Structure-based design of a new class of anti-inflammatory drugs: Secretory phospholipase A2 inhibitors, SPI , 1999 .

[32]  S. Lin-Shiau,et al.  Suramin inhibits the toxic effects of presynaptic neurotoxins at the mouse motor nerve terminals. , 1999, European journal of pharmacology.

[33]  T. Nevalainen,et al.  Protection by group II phospholipase A2 against Staphylococcus aureus. , 1999, Journal of immunology.

[34]  M. Freissmuth,et al.  G protein antagonists. , 1999, Trends in pharmacological sciences.

[35]  A. Kleinfeld,et al.  The measurement of free fatty acid concentration with the fluorescent probe ADIFAB: A practical guide for the use of the ADIFAB probe , 1999, Molecular and Cellular Biochemistry.

[36]  R. Othman,et al.  Tryptophan-containing mutant of human (group IIa) secreted phospholipase A2 has a dramatically increased ability to hydrolyze phosphatidylcholine vesicles and cell membranes. , 1998, Biochemistry.

[37]  R. Lehrer,et al.  Secretory Phospholipase A2 Is the Principal Bactericide for Staphylococci and Other Gram-Positive Bacteria in Human Tears , 1998, Infection and Immunity.

[38]  Y. Snitko,et al.  High specificity of human secretory class II phospholipase A2 for phosphatidic acid. , 1997, The Biochemical journal.

[39]  R. Othman,et al.  Human non-pancreatic (group II) secreted phospholipase A2 expressed from a synthetic gene in Escherichia coli: characterisation of N-terminal mutants. , 1996, Biochimica et biophysica acta.

[40]  A. IJzerman,et al.  Suramin analogues as subtype-selective G protein inhibitors. , 1996, Molecular pharmacology.

[41]  M. Lazdunski,et al.  Identification of the Binding Domain for Secretory Phospholipases A2 on Their M-type 180-kDa Membrane Receptor * , 1995, The Journal of Biological Chemistry.

[42]  M. Díaz-Guerra,et al.  Bacterial Lipopeptides Induce Nitric Oxide Synthase and Promote Apoptosis through Nitric Oxide-independent Pathways in Rat Macrophages (*) , 1995, The Journal of Biological Chemistry.

[43]  R. Lehrer,et al.  Bactericidal properties of murine intestinal phospholipase A2. , 1995, The Journal of clinical investigation.

[44]  J. J. Rosa,et al.  Structures of free and inhibited human secretory phospholipase A2 from inflammatory exudate. , 1993, Science.

[45]  I. Coppens,et al.  The uptake of the trypanocidal drug suramin in combination with low-density lipoproteins by Trypanosoma brucei and its possible mode of action. , 1993, Acta tropica.

[46]  T. Lane,et al.  Gamma interferon cooperates with lipopolysaccharide to activate mouse splenic macrophages to an antihistoplasma state , 1993, Infection and immunity.

[47]  L. Packer,et al.  Tocopherol analogs suppress arachidonic acid metabolism via phospholipase inhibition. , 1992, The Journal of biological chemistry.

[48]  C. Stoner,et al.  Induction of phospholipase A2 gene expression in human hepatoma cells by mediators of the acute phase response. , 1991, The Journal of biological chemistry.

[49]  W. Ripka,et al.  Molecular modeling in the design of phospholipase A2 inhibitors , 1989, Journal of cellular biochemistry.

[50]  T. Mosmann.  Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. , 1983, Journal of immunological methods.

[51]  H. Kihara.  Studies on phospholipase A in Trimeresurus flaoviridis venom. III. Purification and some properties of phospholipase A inhibitor in Habu serum. , 1976, Journal of biochemistry.

[52]  J. Vidal,et al.  Zymogen-catalyzed hydrolysis of monomeric substrates and the presence of a recognition site for lipid-water interfaces in phospholipase A2. , 1974, Biochemistry.

[53]  S. Jancar,et al.  Immune complex-mediated tissue injury: a multistep paradigm. , 2005, Trends in immunology.

[54]  Robert,et al.  Induction of Phospholipase A 2 Gene Expression in Human Hepatoma Cells by Mediators of the Acute Phase Response * , 2001 .

[55]  M. Pintore,et al.  A molecular modeling and 3D QSAR study of a large series of indole inhibitors of human non-pancreatic secretory phospholipase A2. , 2001, European journal of medicinal chemistry.

[56]  R. Schevitz,et al.  Structure-based design of a new class of anti-inflammatory drugs: secretory phospholipase A(2) inhibitors, SPI. , 1999, Biochimica et biophysica acta.

[57]  C. Nathan,et al.  Nitric oxide and macrophage function. , 1997, Annual review of immunology.

[58]  M. Christian,et al.  New drugs in non-Hodgkin's lymphoma. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

[59]  G. Atsumi,et al.  Regulatory functions of phospholipase A2. , 1997, Critical reviews in immunology.

[60]  J. Browning,et al.  Extracellular phospholipase A2 expression and inflammation: the relationship with associated disease states. , 1993, Journal of lipid mediators.

[61]  D. Jodrell,et al.  Suramin, an active drug for prostate cancer: interim observations in a phase I trial. , 1993, Journal of the National Cancer Institute.

[62]  L. M. Deenen,et al.  THE SUBSTRATE SPECIFICITY OF PHOSPHOLIPASE A. , 1963 .

[63]  J. Schneider.  [Treatment of human African trypanosomiasis]. , 1963, Bulletin of the World Health Organization.